Larotrectinib: First Global Approval
Larotrectinib (VITRAKVI ® ) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosin...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2019-02, Vol.79 (2), p.201-206 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 2 |
| container_start_page | 201 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 79 |
| creator | Scott, Lesley J. |
| description | Larotrectinib (VITRAKVI
®
) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (
NTRK
) gene fusions. In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a
NTRK
gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tumours with
NTRK
gene fusion proteins has been submitted in the EU. This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and paediatric patients with solid tumours that have
NTRK
gene fusion. |
| doi_str_mv | 10.1007/s40265-018-1044-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179362893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2191284009</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-98cf1a6f6460b86ed3279ec5e5a41ea2b6d711e1efd8a6e801b367ffb03ffb2f3</originalsourceid><addsrcrecordid>eNp1kM9LwzAUx4Mobk7_AC8y0IOX6HtJmx_extApDLzoOaRtKh1dO5NW5n9vRqeC4CWPkM_7vrwPIecINwggb0MCTKQUUFGEJKHbAzJGlJqiTuGQjAGQUSGEHJGTEFa7q071MRlxEDxVXI7J1dL6tvMu76qmyu6mD5UP3XRRt5mtp7PNxrcftj4lR6Wtgzvb1wl5fbh_mT_S5fPiaT5b0pxL1lGt8hKtKEUiIFPCFZxJ7fLUpTZBZ1kmCono0JWFssIpwIwLWZYZ8Hiwkk_I9ZAbx773LnRmXYXc1bVtXNsHw-JuXDCleUQv_6CrtvdN_F2kNDKVAOhI4UDlvg3Bu9JsfLW2_tMgmJ1CMyg0UaHZKTTb2HOxT-6ztSt-Or6dRYANQIhPzZvzv6P_T_0C6S16sw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2191284009</pqid></control><display><type>article</type><title>Larotrectinib: First Global Approval</title><source>SpringerLink Journals - AutoHoldings</source><creator>Scott, Lesley J.</creator><creatorcontrib>Scott, Lesley J.</creatorcontrib><description>Larotrectinib (VITRAKVI
®
) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (
NTRK
) gene fusions. In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a
NTRK
gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tumours with
NTRK
gene fusion proteins has been submitted in the EU. This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and paediatric patients with solid tumours that have
NTRK
gene fusion.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-018-1044-x</identifier><identifier>PMID: 30635837</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>AdisInsight Report ; Agreements ; Cancer therapies ; Collaboration ; Drug dosages ; Enzyme inhibitors ; FDA approval ; Gene fusion ; Internal Medicine ; Kinases ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Morbidity ; Mutation ; Oncology ; Oral administration ; Patients ; Pharmacology/Toxicology ; Pharmacotherapy ; Protein-tyrosine kinase receptors ; Proteins ; Solid tumors ; Surgery ; Tropomyosin ; Tumors ; Tyrosine</subject><ispartof>Drugs (New York, N.Y.), 2019-02, Vol.79 (2), p.201-206</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Copyright Springer Nature B.V. Feb 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-98cf1a6f6460b86ed3279ec5e5a41ea2b6d711e1efd8a6e801b367ffb03ffb2f3</citedby><cites>FETCH-LOGICAL-c372t-98cf1a6f6460b86ed3279ec5e5a41ea2b6d711e1efd8a6e801b367ffb03ffb2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-018-1044-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-018-1044-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30635837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scott, Lesley J.</creatorcontrib><title>Larotrectinib: First Global Approval</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Larotrectinib (VITRAKVI
®
) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (
NTRK
) gene fusions. In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a
NTRK
gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tumours with
NTRK
gene fusion proteins has been submitted in the EU. This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and paediatric patients with solid tumours that have
NTRK
gene fusion.</description><subject>AdisInsight Report</subject><subject>Agreements</subject><subject>Cancer therapies</subject><subject>Collaboration</subject><subject>Drug dosages</subject><subject>Enzyme inhibitors</subject><subject>FDA approval</subject><subject>Gene fusion</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Morbidity</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Oral administration</subject><subject>Patients</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Protein-tyrosine kinase receptors</subject><subject>Proteins</subject><subject>Solid tumors</subject><subject>Surgery</subject><subject>Tropomyosin</subject><subject>Tumors</subject><subject>Tyrosine</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kM9LwzAUx4Mobk7_AC8y0IOX6HtJmx_extApDLzoOaRtKh1dO5NW5n9vRqeC4CWPkM_7vrwPIecINwggb0MCTKQUUFGEJKHbAzJGlJqiTuGQjAGQUSGEHJGTEFa7q071MRlxEDxVXI7J1dL6tvMu76qmyu6mD5UP3XRRt5mtp7PNxrcftj4lR6Wtgzvb1wl5fbh_mT_S5fPiaT5b0pxL1lGt8hKtKEUiIFPCFZxJ7fLUpTZBZ1kmCono0JWFssIpwIwLWZYZ8Hiwkk_I9ZAbx773LnRmXYXc1bVtXNsHw-JuXDCleUQv_6CrtvdN_F2kNDKVAOhI4UDlvg3Bu9JsfLW2_tMgmJ1CMyg0UaHZKTTb2HOxT-6ztSt-Or6dRYANQIhPzZvzv6P_T_0C6S16sw</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Scott, Lesley J.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190201</creationdate><title>Larotrectinib: First Global Approval</title><author>Scott, Lesley J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-98cf1a6f6460b86ed3279ec5e5a41ea2b6d711e1efd8a6e801b367ffb03ffb2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>AdisInsight Report</topic><topic>Agreements</topic><topic>Cancer therapies</topic><topic>Collaboration</topic><topic>Drug dosages</topic><topic>Enzyme inhibitors</topic><topic>FDA approval</topic><topic>Gene fusion</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Morbidity</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Oral administration</topic><topic>Patients</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Protein-tyrosine kinase receptors</topic><topic>Proteins</topic><topic>Solid tumors</topic><topic>Surgery</topic><topic>Tropomyosin</topic><topic>Tumors</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scott, Lesley J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scott, Lesley J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Larotrectinib: First Global Approval</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>79</volume><issue>2</issue><spage>201</spage><epage>206</epage><pages>201-206</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Larotrectinib (VITRAKVI
®
) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (
NTRK
) gene fusions. In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a
NTRK
gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. A registration application for the use of larotrectinib in paediatric and adult patients with locally advanced or metastatic solid tumours with
NTRK
gene fusion proteins has been submitted in the EU. This article summarizes the milestones in the development of larotrectinib leading to its first approval for the treatment of adult and paediatric patients with solid tumours that have
NTRK
gene fusion.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30635837</pmid><doi>10.1007/s40265-018-1044-x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2019-02, Vol.79 (2), p.201-206 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179362893 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | AdisInsight Report Agreements Cancer therapies Collaboration Drug dosages Enzyme inhibitors FDA approval Gene fusion Internal Medicine Kinases Medicine Medicine & Public Health Metastases Metastasis Morbidity Mutation Oncology Oral administration Patients Pharmacology/Toxicology Pharmacotherapy Protein-tyrosine kinase receptors Proteins Solid tumors Surgery Tropomyosin Tumors Tyrosine |
| title | Larotrectinib: First Global Approval |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T23%3A41%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Larotrectinib:%20First%20Global%20Approval&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Scott,%20Lesley%20J.&rft.date=2019-02-01&rft.volume=79&rft.issue=2&rft.spage=201&rft.epage=206&rft.pages=201-206&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-018-1044-x&rft_dat=%3Cproquest_cross%3E2191284009%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2191284009&rft_id=info:pmid/30635837&rfr_iscdi=true |